Part,  Chapter, Paragraph

 1   II,     5.  2.  6| introduction of new myocite damage markers (troponins), has changed
 2   II,     5.  6.  3|       turnover as assessed by bone markers. Frailty and co-morbidity
 3   II,     5.  7.  1|         pathologic abnormalities~• markers of kidney damage~urinary
 4   II,     5.  9.  2|            prevalence of objective markers of atopic diseases and investigated
 5   II,     5.  9.  4|           PL), and Amsterdam (NL). Markers within the same model were
 6   II,     5.  9.  4|        were often well correlated. Markers of inflammation in the in
 7   II,     5.  9.  4|           allergy and inflammation markers was generally poor. This
 8   II,     5.  9.  7|         2004): Allergy, asthma and markers of infections among Albanian
 9   II,     5. 12.  5|    generations. In fact, HBV serum markers have considerably declined
10   II,     9.  1.  2|            malformations and “soft markers”. For Down Syndrome, a combined
11  III,    10.  2.  1|     hepatitis B. The prevalence of markers for HBV infection varies
12  III,    10.  2.  1|            extent than that of HCV markers, possibly due to differences
13  III,    10.  2.  4|            variation to biological markers of all types and systems
14  III,    10.  4.  2|          well as the usefulness of markers of proven validity intermediate
15   IV,    11.  5.  3|             With respect to tumour markers carried out for donor evaluation,
16   IV,    11.  5.  3|               Figure 11.17. Tumour markers in organs transplants number